|
22 Mar 2021 |
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
|
|
22 Mar 2021 |
Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan
|
|
20 Mar 2021 |
Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose
|
|
19 Mar 2021 |
BlueSky Immunotherapies GmbH (Ltd.): Phase 1 clinical trial for delNS HPV 16
|
|
18 Mar 2021 |
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
|
|
18 Mar 2021 |
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
|
|
16 Mar 2021 |
AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine
|
|
16 Mar 2021 |
Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate
|
|
16 Mar 2021 |
Meissa Announces IND Clearance for Phase 1 Study of Intranasal Live Attenuated Vaccine Candidate for COVID-19
|
|
15 Mar 2021 |
Update on the safety of COVID-19 Vaccine AstraZeneca
|
|
12 Mar 2021 |
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
|
|
12 Mar 2021 |
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy
|
|
12 Mar 2021 |
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
|
|
11 Mar 2021 |
AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial
|
|
11 Mar 2021 |
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
|
|
09 Mar 2021 |
Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial
|
|
09 Mar 2021 |
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
|
|
04 Mar 2021 |
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
|
|
04 Mar 2021 |
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
|
|
03 Mar 2021 |
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%
|
|
03 Mar 2021 |
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
|
|
28 Feb 2021 |
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
|
|
28 Feb 2021 |
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
|
|
28 Feb 2021 |
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
|
|
25 Feb 2021 |
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
|
